For Healthcare Professionals

A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer


About the study

A study to assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer in terms of efficacy, safety and tolerability

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria:

  1. Aged at least 18 years.
  2. Documented evidence of NSCLC (stage IIIB/IV disease)
  3. Disease progression or recurrence after both a platinum-based chemotherapy and at least 1 additional regimen for treatment of NSCLC
  4. World Health Organisation (WHO) Performance Status of 0 or 1
  5. Estimated life expectancy of more than 12 weeks
  6. Patient's tumour sample must be PD-L1 positive (≥25%of tumour cells with membrane staining (Cohort 1 and 2) or PD-L1 positive with ≥90% of tumour cells with membrane staining (Cohort 3))


Exclusion Criteria:

  1. Prior exposure to any anti-PD-1 or anti-PD-L1 antibody
  2. Brain metastases or spinal cord compression or unless asymptomatic, treated and stable (not requiring steroids).
  3. Active or prior autoimmune disease or history of immunodeficiency
  4. Evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses or active infections including hepatitis B, C and HIV.
  5. Evidence of uncontrolled illness such as symptomatic congestive heart failure, uncontrolled hypertension or unstable angina pectoris.
  6. Any unresolved toxicity CTCAE >Grade 2 from previous anti-cancer therapy.
  7. Any prior Grade ≥3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE >Grade 1
  8. Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis)

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Non-Small Cell Lung Cancer

Age (in years)

18 - 130


Phase 2

Participants needed


Est. Completion Date

Jun 28, 2024

Treatment type



AstraZeneca identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.